Article
Pharmacoeconomics Open  (2021)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile

Espinoza MA.; Rojas, R.; Zaupa, Alessandro; Balmaceda C.